Type of mutations detected at baseline. Mutations detected before ponatinib initiation (baseline) in 363 patients enrolled in the PACE trial, arranged from the top according to the most frequently detected by Sanger sequencing. Low-level mutations were detected by MS but not by Sanger sequencing, and therefore represent between 0.05% and 10% of the BCR-ABL1 species within the sample.